On October 12, 2022, Gerald W. Crabtree, the chief scientific officer of PharmaCyte Biotech, Inc. resigned from his position as an employee of the company. In connection with Mr. Crabtree's departure, on October 12, 2022, the company entered into a Release Agreement with Mr. Crabtree. The Release Agreement becomes irrevocable seven days after execution of the Release Agreement and becomes effective on October 20, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.96 USD | -5.77% | +0.51% | -9.26% |
Jun. 17 | MyMD Pharmaceuticals, Inc. announced that it has received $14 million in funding from PharmaCyte Biotech, Inc. | CI |
May. 23 | MyMD Pharmaceuticals, Inc. amended terms of the transaction | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.26% | 16.57M | |
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+2.04% | 224B | |
+13.31% | 218B | |
+8.48% | 168B |
- Stock Market
- Equities
- PMCB Stock
- News PharmaCyte Biotech, Inc.
- PharmaCyte Biotech, Inc. Announces Resignation of Gerald W. Crabtree as Chief Scientific Officer